SUNPHARMA

Sun Pharmaceutical Industries Cash Flow

₹1,773.60-1.69%
Market cap
₹4.26 lakh crore
P/E
35.2
P/B
5.09
ROE
14.7%
Dividend yield
0.28%

In the year ended Mar 2022, Sun Pharmaceutical Industries generated ₹1,400 crore from operating activities, invested ₹600 crore and paid out ₹550 crore on financing activities. Net cash flow for the year was ₹250 crore. Free cash flow was ₹950 crore.

Sun Pharmaceutical Industries cash flow statement

Financial years, newest first. Negative figures are cash outflows.

Sun Pharmaceutical Industries cash flows (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activities1,4004,95912,13514,07212,419
Cash from investing activities-600-7,944-690-5,306-11,344
Cash from financing activities-5502,376-6,710-7,906-2,513
Net cash flow250-4514,661983-661
Capital expenditure—————
Free cash flow9502,8749,93311,9448,810

Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Sun Pharmaceutical Industries cash flow — frequently asked questions

What is Sun Pharmaceutical Industries' operating cash flow?

Sun Pharmaceutical Industries' cash flow from operating activities was ₹1,400 crore in the year ended Mar 2022, fell 71.77% from ₹4,959 crore in Mar 2023.

What is Sun Pharmaceutical Industries' free cash flow?

Sun Pharmaceutical Industries' free cash flow — operating cash flow minus capital expenditure — was ₹950 crore in Mar 2022.

How much did Sun Pharmaceutical Industries spend on investing activities?

Net cash used in investing activities was ₹600 crore in Mar 2022. This covers capital expenditure, acquisitions and the purchase or sale of investments.

Same Data For Peers

Trade Sun Pharmaceutical Industries With ATS

Track SUNPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.